HOME >> MEDICINE >> NEWS
NIAID researchers show how promising TB drug works

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).

"PA-824, now in early stage clinical trials, holds promise for shortening the TB treatment regimen, which is currently cumbersome and lengthy," says NIAID Director Anthony S. Fauci, M.D. "This new finding will allow a streamlined approach for making improved versions of the drug."

"Previously, we were flying blind in trying to optimize PA-824 in a rational way because we didn't know which M. tb protein was the target of PA-824's action," says NIAID scientist Clifton Barry, III, Ph.D., who headed the research team.

In preclinical testing, PA-824 showed evidence of being effective against both actively dividing and slow-growing M. tb, giving rise to optimism that the compound may be useful in treating both active and latent TB. (For information about the first clinical trial of PA-824, see June 14, 2005, NIAID press release: http://www3.niaid.nih.gov/news/newsreleases/2005/tb_pa_824.htm.)

PA-824 must be chemically activated in the bacterium before it exerts its anti-tubercular effect, notes Dr. Barry. Earlier research had sketched out the first few steps in this process, but Dr. Barry and his colleagues wanted to pinpoint the precise protein that binds PA-824 and transforms it into a lethal molecule for TB.

The scientists approached the problem indirectly by searching for M. tb mutants that resisted the killing power of PA-824. The team confirmed previous research suggesting that resistance usually occurs when M. tb lacks components
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Dec-2005


Page: 1 2 3

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. NIAID awards $4 million to develop anti-radiation treatments
5. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
6. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
7. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
8. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
9. NIAID media availability: Understanding influenza infection
10. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
11. NIAID launches first Phase II trial of a global HIV/AIDS vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... The Stevie® Awards, organizer ... annual Women|Future Conference and the advisory board that is curating the ... and their organizations in tomorrow's marketplace. , The mission of the conference is ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... Many people ... does sciatica actually mean? The term itself is widely misunderstood and so are its ... of Atlantic Spine Center. , “Sciatica is commonly used to ...
(Date:6/13/2019)... YORK (PRWEB) , ... June ... ... 3D printing—including medical and dental implants, additive manufacturing (AM)-enabled tissue fabrication, patient-matched ... day, physicians are using AM medical technologies to improve patient care. Children ...
(Date:6/12/2019)... ... 2019 , ... NDA Partners Chairman Carl Peck, MD, announced ... of experience in quality systems development, quality systems management, auditing, FDA QSR/GMP, ISO ... Partners as an Expert Consultant. Her experience includes quality systems development and management ...
(Date:6/12/2019)... ... June 12, 2019 , ... We are excited to ... UPMC Pinnacle, a top-rated healthcare system, providing cutting-edge fertility treatment to patients in ... many premier insurance plans because of our commitment to evidence-based medicine and best ...
Breaking Medicine News(10 mins):
(Date:6/16/2019)... ... June 14, 2019 , ... AVIE! MedSpa and Laser Center is proud to ... and radiofrequency treatment for achieving dramatic improvements to the texture and tightness of skin ... stimulates the skin with tiny needles, spurring vibrant new collagen growth for a wide ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... PET Centre, Chulabhorn Hospital announced today a research collaboration to investigate the accumulation ... individuals. The first subjects have been recruited and imaged. LMI and Chulabhorn Royal ...
(Date:6/13/2019)... KANSAS CITY, Mo. (PRWEB) , ... June 13, ... ... selected Caravan Health as a Prime awardee of the Network of Quality Improvement ... over the next five years. As a Prime NQIIC awardee partnering with ...
Breaking Medicine Technology:
Cached News: